Literature DB >> 25534199

Bone: Fracture risk in the JUPITER trial--statin treatment or not?

Peter Vestergaard1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25534199     DOI： 10.1038/nrendo.2014.232

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  9 in total

1.  Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial.

Authors:  Jessica M Peña; Sara Aspberg; Jean MacFadyen; Robert J Glynn; Daniel H Solomon; Paul M Ridker
Journal:  JAMA Intern Med       Date:  2015-02       Impact factor: 21.873

2.  C-reactive protein, bone loss, fracture, and mortality in elderly women: a longitudinal study in the OPRA cohort.

Authors:  S Berglundh; L Malmgren; H Luthman; F McGuigan; K Åkesson
Journal:  Osteoporos Int       Date:  2014-11-20       Impact factor: 4.507

3.  Statin but not non-statin lipid-lowering drugs decrease fracture risk: a nation-wide case-control study.

Authors:  L Rejnmark; P Vestergaard; L Mosekilde
Journal:  Calcif Tissue Int       Date:  2006-07-24       Impact factor: 4.333

4.  Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark.

Authors:  Peter Vestergaard; Lars Rejnmark; Leif Mosekilde
Journal:  Osteoporos Int       Date:  2004-06-12       Impact factor: 4.507

Review 5.  Statins and fracture risk. A systematic review.

Authors:  Sengwee Toh; Sonia Hernández-Díaz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-06       Impact factor: 2.890

6.  Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

Authors:  Deborah Grady; David Herrington; Vera Bittner; Roger Blumenthal; Michael Davidson; Mark Hlatky; Judith Hsia; Stephen Hulley; Alan Herd; Steven Khan; L Kristin Newby; David Waters; Eric Vittinghoff; Nanette Wenger
Journal:  JAMA       Date:  2002-07-03       Impact factor: 56.272

7.  Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

Authors:  Paul M Ridker; Eleanor Danielson; Francisco Ah Fonseca; Jacques Genest; Antonio M Gotto; John Jp Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G Macfadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

8.  The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein.

Authors:  U Beisiegel; W Weber; G Ihrke; J Herz; K K Stanley
Journal:  Nature       Date:  1989-09-14       Impact factor: 49.962

9.  LRP8 mediates Wnt/β-catenin signaling and controls osteoblast differentiation.

Authors:  Juan Zhang; Xiaofei Zhang; Long Zhang; Fangfang Zhou; Maarten van Dinther; Peter Ten Dijke
Journal:  J Bone Miner Res       Date:  2012-10       Impact factor: 6.741
  9 in total
  1 in total

1.  Optimal serum cholesterol concentrations are associated with accelerated bone loss in African ancestry men.

Authors:  A L Kuipers; I Miljkovic; R Evans; C H Bunker; A L Patrick; J M Zmuda
Journal:  Osteoporos Int       Date:  2015-11-24       Impact factor: 4.507
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.